Eligo raises $20M to take bacteria-killing CRISPR drug into clinic – FierceBiotech
FierceBiotech |
Eligo raises $20M to take bacteria-killing CRISPR drug into clinic
FierceBiotech The potential for CRISPR/Cas9 to enable targeted attacks on bacteria—sniper shots compared to antibiotic WMDs—has raised hopes the gene editing technology can address the antibiotic crisis. It has also attracted the attention of biotechs including … French Biotech Gets $20M to Treat the Microbiome with CRISPR Nanobots Khosla Ventures makes first investment in France, leads $18 million round in Eligo Bioscience Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the … |
